The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), continues to spread globally.
With this spread, new variants and strains have emerged, posing a threat to the recently developed and distributed SARS-CoV-2 vaccines' efficacy.
Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.
In the study, published in the pre-print server medRxiv*, the team examined patterns of mutations that emerged in the SARS-CoV-2 genome during the pandemic.
Between December 2019 and October 2020, the virus's evolution worldwide involved a highly susceptible new host population. A mutation D614G (Asp614-to-Gly) in the viral spike protein hastened the spread of the virus.
From there, few mutations were epidemiologically significant without impacting SARS-CoV-2's pathogenesis. However, these mutations were characterized by a mutational pattern of slow and selectively-neutral random genetic drift.
Since October 2020, SARS-CoV-2 has mutation several times. Currently, three variants are actively spreading – the U.K. variant called B.1.1.7 with many mutations in the fall of 2020, the South African variant called B.1.351, and the Brazil variant called P.1.
The U.K. variant spreads faster and easier than other variants. In January 2021, scientists said that the variant might be linked to an increased risk of death than other variant viruses. It has spread to many countries worldwide.
The B.1.351 variant is known to be resistant to the effects of vaccines and therapies against COVID-19. Meanwhile, the P.1 variant emerged in travelers from Brazil in early January. This variant contains a set of additional mutations that may affect its ability to be recognized by antibodies.
In the study, the B.1.17 or 501Y.V1 variant is referred to as V1, B.1.351 or 501Y.V2 variant is V2, and P.1 or 501Y.V3 variant is referred to as V3.
To date, studies suggest that antibodies produced through vaccination with approved vaccines recognize these variants, but further investigation is ongoing.
The study aimed to determine the evolutionary capacity of SARS-CoV-2 to adapt to both rising population immunity and infection control measures like social distancing and vaccination.
The researchers examined patterns of mutations that emerged in SARS-CoV-2 genomes during the pandemic.
The team used a suite of phylogenetics-based natural selection analysis techniques to examine positive selection patterns within the three lineages' protein-coding sequences.
The study findings showed the emergence of the 501Y lineages concurred with a substantial global change in positive selection signals. This means a general shift in the selective environment within which SARS-CoV-2 is evolving.
They also found a significant shift in the selective forces acting on SARS-CoV-2 genes. Further, the team revealed that the adaptive evolution of the 501Y lineages unites between lineages. This study highlights the essence of surveillance on how 501Y lineage members evolve similar stages to ensure their survival and persistence.
The sudden emergence of the 501Y lineages
The team explained that in the first months of the pandemic, there were no arising mutations. This was the languid pace of the viral evolution. The pandemic's start was like a fitness peak for the virus concerning its capacity to infect and transmit between humans.
Since October 2020, however, the sudden emergence of the 501Y lineages has led to skyrocketing cases worldwide. The V1, V2, and V3 caused the virus's faster transmission, which has now reached 192 countries and regions.
"Given the numbers of infections that had occurred by October, all of these individual mutations, and even all of the potentially epistatically interacting pairs of these mutations, would have arisen independently," the researchers explained.
To date, the number of cases has reached over 117 million and 2.59 million deaths. The United States reports the highest number of infections, topping 29 million. The other countries with skyrocketing cases include India, with 11.22 million cases; Brazil, with 11 million cases, Russia, with 4.28 million cases, and the U.K., with 4.23 million cases.
medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
- COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) – https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
- Martin, D., Weaver, S., Tegally, H., et al. (2021). The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape. medRxiv. https://www.medrxiv.org/content/10.1101/2021.02.23.21252268v1
Posted in: Medical Research News | Disease/Infection News
Tags: ACE2, Amino Acid, Antibodies, Cell, Coronavirus, Coronavirus Disease COVID-19, Efficacy, Evolution, Gene, Genes, Genetic, Genome, Infection Control, Mutation, Pandemic, Protein, Receptor, Respiratory, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Spike Protein, Syndrome, Virus
Angela Betsaida B. Laguipo
Angela is a nurse by profession and a writer by heart. She graduated with honors (Cum Laude) for her Bachelor of Nursing degree at the University of Baguio, Philippines. She is currently completing her Master's Degree where she specialized in Maternal and Child Nursing and worked as a clinical instructor and educator in the School of Nursing at the University of Baguio.
Source: Read Full Article